Your Compliance Checklist: 7 Steps to Prepare Now
- Audit your current drug testing policy. Search your policy documents, vendor agreements, and any Safety Council submissions for references to a "DOT 5-panel test." Flag every instance for revision, as that terminology becomes outdated the moment fentanyl is officially added.
- Confirm your regulatory status. Determine your DOT status (whether your company falls under DOT jurisdiction directly, through contracts with DOT-regulated entities, or through voluntary adoption of DOT standards), as it affects your obligations. If you're unsure, consult your TPA or legal counsel to confirm.
- Contact your drug testing provider. Verify they can add fentanyl and norfentanyl to your DOT packages at the cutoff levels stated in the final ruling. Ask about their timeline for implementation with labs, as not every lab will be ready on day one. To test immediately.
- Coordinate with the Medical Review Officer. Discuss the new MRO procedures for codeine and morphine results, including the removal of the clinical evidence requirement. Confirm that the MRO understands how fentanyl-positive results will be reviewed.
- Notify your Third-Party Administrator. Ensure their systems incorporate the updated panel, the new analyte nomenclature (standardized names, codes, and abbreviations for substances), and the revised morphine cutoff. Get written confirmation that the updates are underway.
- Update employee handbooks and onboarding materials. Ensure that any documentation referencing the DOT panel, tested substances, or specimen types is revised before the effective date.
- Get ready for more positive results, as fentanyl is widespread in the illegal supply. Increasing testing will reveal positives that were previously undetectable. Ensure your adverse action process, SAP referral protocol, and return-to-duty procedures are well-documented, up to date, and defensible.
Component | Current DOT Panel | Proposed DOT Panel |
Marijuana (THC) | Yes | Yes |
Cocaine | Yes | Yes |
Opiates (codeine, morphine) | Yes | Yes (revised morphine cutoff: 4,000 ng/mL confirmatory) |
Amphetamines/methamphetamines | Yes | Yes |
PCP | Yes | Yes |
Fentanyl | No | Yes (urine and oral fluid) |
Norfentanyl | No | Yes (urine only) |
Oral fluid testing | Pending lab certification | Pending lab certification (fentanyl added when available) |
How KRESS Helps You Stay Ahead
Here is what your KRESS team handles when a rule change like this is finalized:
- Confirm your lab can test for fentanyl and norfentanyl at the required cutoff levels, and flags any readiness gaps before the effective date
- Update your account configuration to reflect the expanded panel, so your orders and results align with the new requirements from day one
- Coordinate with your MRO to confirm procedures are aligned for fentanyl-positive results, including the revised codeine/morphine review process
- Review your policy documents and flag any references to the "five-panel" structure or outdated terminology that need revision
- Handle Safety Council and operator-specific documentation updates for oil and gas and construction employers managing multi-site compliance
For employers juggling Safety Council approvals, operator-specific requirements, and multi-site compliance, our state-by-state compliance guide and layered screening services are tailored to the environment where you actually operate. When you call KRESS, you reach a named person who knows your industry: no ticket queues, no generic hold music.